Literature DB >> 19251093

Inhibition of 4E-BP1 sensitizes U87 glioblastoma xenograft tumors to irradiation by decreasing hypoxia tolerance.

Ludwig Dubois1, Michaël G Magagnin, Arjen H G Cleven, Sherry A Weppler, Beat Grenacher, Willy Landuyt, Natasja Lieuwes, Philippe Lambin, Thomas A Gorr, Marianne Koritzinsky, Bradly G Wouters.   

Abstract

PURPOSE: Eukaryotic initiation factor 4E (eIF4E) is an essential rate-limiting factor for cap-dependent translation in eukaryotic cells. Elevated eIF4E activity is common in many human tumors and is associated with disease progression. The growth-promoting effects of eIF4E are in turn negatively regulated by 4E-BP1. However, although 4E-BP1 harbors anti-growth activity, its expression is paradoxically elevated in some tumors. The aim of this study was to investigate the functional role of 4E-BP1 in the context of solid tumors. METHODS AND MATERIALS: In vitro and in vivo growth properties, hypoxia tolerance, and response to radiation were assessed for HeLa and U87 cells, after stable expression of shRNA specific for 4E-BP1.
RESULTS: We found that loss of 4E-BP1 expression did not significantly alter in vitro growth but did accelerate the growth of U87 tumor xenografts, consistent with the growth-promoting function of deregulated eIF4E. However, cells lacking 4E-BP1 were significantly more sensitive to hypoxia-induced cell death in vitro. Furthermore, 4E-BP1 knockdown cells produced tumors more sensitive to radiation because of a reduction in the viable fraction of radioresistant hypoxic cells. Decreased hypoxia tolerance in the 4E-BP1 knockdown tumors was evident by increased cleaved caspase-3 levels and was associated with a reduction in adenosine triphosphate (ATP).
CONCLUSIONS: Our results suggest that although tumors often demonstrate increases in cap-dependent translation, regulation of this activity is required to facilitate energy conservation, hypoxia tolerance, and tumor radioresistance. Furthermore, we suggest that targeting translational control may be an effective way to target hypoxic cells and radioresistance in metabolically hyperactive tumors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19251093     DOI: 10.1016/j.ijrobp.2008.12.003

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  17 in total

1.  The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis.

Authors:  T L Ng; G Leprivier; M D Robertson; C Chow; M J Martin; K R Laderoute; E Davicioni; T J Triche; P H B Sorensen
Journal:  Cell Death Differ       Date:  2011-09-23       Impact factor: 15.828

2.  Protein phosphatase 2A promotes endothelial survival via stabilization of translational inhibitor 4E-BP1 following exposure to tumor necrosis factor-α.

Authors:  Carla Janzen; Suvajit Sen; Janis Cuevas; Srinivasa T Reddy; Gautam Chaudhuri
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

3.  Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.

Authors:  F Volpin; J Casaos; J Sesen; A Mangraviti; J Choi; N Gorelick; J Frikeche; T Lott; R Felder; S J Scotland; T S K Eisinger-Mathason; H Brem; B Tyler; N Skuli
Journal:  Oncogene       Date:  2016-12-12       Impact factor: 9.867

Review 4.  Eukaryotic initiation factor 4E-binding protein 1 (4E-BP1): a master regulator of mRNA translation involved in tumorigenesis.

Authors:  J Musa; M F Orth; M Dallmayer; M Baldauf; C Pardo; B Rotblat; T Kirchner; G Leprivier; T G P Grünewald
Journal:  Oncogene       Date:  2016-02-01       Impact factor: 9.867

5.  The Clinical and Prognostic Significance of Activated AKT-mTOR Pathway in Human Astrocytomas.

Authors:  Elias A El Habr; Christos Adamopoulos; Georgia Levidou; Aggeliki A Saetta; Penelope Korkolopoulou; Christina Piperi
Journal:  Neurol Res Int       Date:  2012-02-21

6.  Independent and functional validation of a multi-tumour-type proliferation signature.

Authors:  M H W Starmans; N G Lieuwes; P N Span; S Haider; L Dubois; F Nguyen; H W van Laarhoven; F C G J Sweep; B G Wouters; P C Boutros; P Lambin
Journal:  Br J Cancer       Date:  2012-06-21       Impact factor: 7.640

7.  eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer.

Authors:  Min-Wu Chao; Li-Ting Wang; Chin-Yu Lai; Xiao-Ming Yang; Ya-Wen Cheng; Kuo-Hsiung Lee; Shiow-Lin Pan; Che-Ming Teng
Journal:  Oncotarget       Date:  2015-09-15

8.  Stabilization of 4E-BP1 by PI3K kinase and its involvement in CHK2 phosphorylation in the cellular response to radiation.

Authors:  Zi-Jian Yu; Hui-Hui Luo; Zeng-Fu Shang; Hua Guan; Bei-Bei Xiao; Xiao-Dan Liu; Yu Wang; Bo Huang; Ping-Kun Zhou
Journal:  Int J Med Sci       Date:  2017-04-09       Impact factor: 3.738

Review 9.  Surviving hypoxia by modulation of mRNA translation rate.

Authors:  Michael Fähling
Journal:  J Cell Mol Med       Date:  2009-08-08       Impact factor: 5.310

10.  Requirement for the eIF4E binding proteins for the synergistic down-regulation of protein synthesis by hypertonic conditions and mTOR inhibition.

Authors:  Michael J Clemens; Androulla Elia; Simon J Morley
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.